Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

SoftBank Group posted a surprise quarterly loss Wednesday and the Japanese company’s revenue also missed analysts’ estimates.

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

SoftBank Group posted a surprise quarterly loss Wednesday and the Japanese company’s revenue also missed analysts’ estimates.

SoftBank Group posted a surprise quarterly loss Wednesday and the Japanese company’s revenue also missed analysts’ estimates.

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

Weight loss medication has taken the world by storm and helped many overweight people. But for some, significant weight loss also comes with a loss of muscle mass and can lead to an increased risk of ...

BigBear.ai (BBAI), a provider of artificial intelligence (AI)-powered decision intelligence solutions, has recently scored ...

Mad About The Boy' with Renee Zellweger taking on a fourth installment & new romances with a younger guy and son's teacher ...

Super Bowl advertising is a difficult assignment for marketers and agencies. Year after year, brands step onto the biggest ...